Skip to main
GPCR
GPCR logo

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics Inc is focused on developing oral small-molecule therapeutics, specifically targeting G-protein coupled receptors (GPCRs) for chronic diseases with unmet needs, which positions the company strongly in a lucrative market. Recent positive outcomes from its phase 3 trial for orforglipron demonstrated improved gastrointestinal tolerability and favorable liver and cardiovascular safety profiles, all contributing to a significant stock price increase of over 25% following the top-line results. The combination of a differentiated technology platform and promising clinical trial results provides an optimistic outlook on Structure Therapeutics's potential for future growth and performance in the biopharmaceutical sector.

Bears say

Structure Therapeutics Inc. currently faces significant financial challenges, with net losses expected to continue at least until commercialization and likely through the early launch phase, creating a risk concerning its financial stability. The company's market capitalization of approximately $410 million, alongside a 20% decline in share value year-to-date, reflects a broader underestimation of its potential, particularly regarding aleniglipron and its preclinical pipeline. Additionally, while initial clinical data suggests some advantages over existing treatments, the ongoing need to secure commercial partnerships in the competitive diabetes and obesity markets underscores substantial operational and strategic uncertainties.

GPCR has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 7 analysts, GPCR has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.